Researchers from the Centenary Institute, in collaboration with the University of Sydney, have developed a powerful new tool ...

In recent years, the therapeutic landscape for hematological malignancies has undergone a profound transformation, driven by ...

The advent of novel cancer care therapies such as chimeric antigen receptor T-cell therapy and bispecific antibodies is transforming the role of pharmacists in enhancing patient care.

The past decade in oncology has been marked by the rise of immunotherapy, which leverages the immune system to attack tumors. For many solid tumors, immune checkpoint inhibitors have supplanted ...

Novel therapies for multiple myeloma (MM), including chimeric antigen receptor T-cell and bispecific antibodies, extend lives but raise concerns about treatment costs and adherence, and they haven't ...

Manmeet Ahluwalia, MD, MBA, FASCO, discussed the significance of National Cancer Research Month and highlighted how ongoing ...

An ICMR-funded trial led by CMC Vellore demonstrated that CAR-T therapy, which uses a patient's own T cells to fight cancer, ...

Collaborative studies among veterinarians and oncology researchers are yielding new insights into NHL, inspiring innovative ...

How do antibody engineers select isotypes? IgG1 has been the most popular choice by far and was used for 13 approved chimeric, humanized or fully human antibodies (compared with only two instances ...

Immunoengineering, which has been beneficial to other medical specialties, could be used in the infectious diseases field to ...

When it comes to relapsed/refractory follicular lymphoma, chimeric antigen receptor (CAR) T-cell therapy has become a go-to treatment for some patients, with its high end durable response rates, and ...